Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.522
Neutral
RSI(14)
53.902
Neutral
STOCH(KDJ)(9,3,3)
81.169
Buy
ATR(14)
2.474
Low Volatility
CCI(14)
78.906
Neutral
Williams %R
47.500
Neutral
TRIX(12,20)
0.057
Sell
StochRSI(14)
73.987
Sell
Rigel Pharmaceuticals Inc
RIGL44.010USD
-0.630-1.41%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
798.52MMarket Cap
6.94P/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of Rigel Pharmaceuticals Inc
Currency: USD Updated: 2025-12-26Key Insights
Rigel Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 48/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 45.33.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rigel Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
6
analysts
Buy
Current Rating
45.333
Target Price
+4.45%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Rigel Pharmaceuticals Inc Highlights
StrengthsRisks
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 49.10% year-on-year.
Turnaround to Profit
The company's performance has turned profitable, with the latest annual net income of USD .
Overvalued
The company’s latest PE is 6.94, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 14.62M shares, decreasing 5.18% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 1.72K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.39.
Financial Health
Currency: USD Updated: 2025-12-26The current financial score of Rigel Pharmaceuticals Inc is 8.68, ranking 44/158 in the Pharmaceuticals industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 69.46M, representing a year-over-year increase of 25.59%, while its net profit experienced a year-over-year increase of 124.62%.
Score
Financials
9.56
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.58
Operational Efficiency
10.00
Growth Potential
8.84
Shareholder Returns
7.41
Rigel Pharmaceuticals Inc's Company Valuation
Currency: USD Updated: 2025-12-26The current valuation score of Rigel Pharmaceuticals Inc is 8.67, ranking 11/158 in the Pharmaceuticals industry. Its current P/E ratio is 6.94, which is 253.27% below the recent high of 24.52 and 1704.27% above the recent low of -111.36.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 48/158
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-26The current earnings forecast score of Rigel Pharmaceuticals Inc is 7.67, ranking 93/158 in the Pharmaceuticals industry. The average price target for Rigel Pharmaceuticals Inc is 42.00, with a high of 69.00 and a low of 24.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
45.333
Target Price
+4.45%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
62
Total
5
Median
6
Average
Company name
Ratings
Analysts
Rigel Pharmaceuticals Inc
RIGL
6
Apple Inc
AAPL
50
Ge Vernova Inc
GEV
34
FMC Corp
FMC
21
Tapestry Inc
TPR
21
Verisk Analytics Inc
VRSK
20
1
2
3
...
13
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-26The current price momentum score of Rigel Pharmaceuticals Inc is 7.31, ranking 82/158 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 50.97 and the support level at 38.33, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
43.668
Buy
MA10
42.733
Buy
MA20
44.100
Sell
MA50
39.459
Buy
MA100
36.999
Buy
MA200
28.145
Buy
Institutional Confidence
Currency: USD Updated: 2025-12-26The current institutional shareholding score of Rigel Pharmaceuticals Inc is 7.00, ranking 44/158 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 80.57%, representing a quarter-over-quarter increase of 1.57%. The largest institutional shareholder is The Vanguard, holding a total of 1.04M shares, representing 5.75% of shares outstanding, with 0.10% decrease in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
BlackRock Institutional Trust Company, N.A.
Armistice Capital LLC
Acadian Asset Management LLC
Marshall Wace LLP
Capitolis Liquid Global Markets LLC
State Street Investment Management (US)
Geode Capital Management, L.L.C.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-26The current risk assessment score of Rigel Pharmaceuticals Inc is 4.25, ranking 89/158 in the Pharmaceuticals industry. The company's beta value is 1.09. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.
Score
Beta vs S&P 500 index
1.09
VaR
+7.22%
240-Day Maximum Drawdown
+36.10%
240-Day Volatility
+78.23%
Return
Best Daily Return
60 days
+33.37%
120 days
+33.37%
5 years
+42.94%
Worst Daily Return
60 days
-11.28%
120 days
-12.09%
5 years
-60.20%
Sharpe Ratio
60 days
+2.36
120 days
+2.48
5 years
+0.47
Risk Assessment
Maximum Drawdown
240 days
+36.10%
3 years
+60.31%
5 years
+85.24%
Return-to-Drawdown Ratio
240 days
+4.35
3 years
+0.95
5 years
+0.03
Skewness
240 days
+1.86
3 years
+1.95
5 years
+0.17
Volatility
Realised Volatility
240 days
+78.23%
5 years
+90.64%
Standardised True Range
240 days
+3.87%
5 years
+3.06%
Downside Risk-Adjusted Return
120 days
+464.74%
240 days
+464.74%
Maximum Daily Upside Volatility
60 days
+85.26%
Maximum Daily Downside Volatility
60 days
+71.07%
Liquidity
Average Turnover Rate
60 days
+2.56%
120 days
+1.91%
5 years
--
Turnover Deviation
20 days
+38.73%
60 days
-34.00%
120 days
-50.77%
Peer Comparison
Pharmaceuticals
Rigel Pharmaceuticals Inc
RIGL
7.59 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Mirum Pharmaceuticals Inc
MIRM
8.78 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
REGN
8.76 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Gilead Sciences Inc
GILD
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
COLL
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
PBH
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of Rigel Pharmaceuticals Inc?
The TradingKey Stock Score provides a comprehensive assessment of Rigel Pharmaceuticals Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Rigel Pharmaceuticals Inc’s performance and outlook.
How do we generate the financial health score of Rigel Pharmaceuticals Inc?
To generate the financial health score of Rigel Pharmaceuticals Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects Rigel Pharmaceuticals Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Rigel Pharmaceuticals Inc.
How do we generate the company valuation score of Rigel Pharmaceuticals Inc?
To generate the company valuation score of Rigel Pharmaceuticals Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Rigel Pharmaceuticals Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Rigel Pharmaceuticals Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Rigel Pharmaceuticals Inc.
How do we generate the earnings forecast score of Rigel Pharmaceuticals Inc?
To calculate the earnings forecast score of Rigel Pharmaceuticals Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Rigel Pharmaceuticals Inc’s future.
How do we generate the price momentum score of Rigel Pharmaceuticals Inc?
When generating the price momentum score for Rigel Pharmaceuticals Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of Rigel Pharmaceuticals Inc’s prices. A higher score indicates a more stable short-term price trend for Rigel Pharmaceuticals Inc.
How do we generate the institutional confidence score of Rigel Pharmaceuticals Inc?
To generate the institutional confidence score of Rigel Pharmaceuticals Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Rigel Pharmaceuticals Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Rigel Pharmaceuticals Inc.
How do we generate the risk management score of Rigel Pharmaceuticals Inc?
To assess the risk management score of Rigel Pharmaceuticals Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of Rigel Pharmaceuticals Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Rigel Pharmaceuticals Inc.
